Literature DB >> 16398058

Antihypertensive effect of manidipine.

Alex Roca-Cusachs1, Filippos Triposkiadis.   

Abstract

Manidipine is a lipophilic, third-generation, highly vasoselective, dihydropyridine (DHP) calcium channel antagonist, which, when given on a once-daily basis, effectively reduces blood pressure (BP) in patients with mild-to-moderate essential hypertension. Manidipine has a gradual onset and a long duration of action, effectively maintaining reduced BP levels throughout the 24-hour dosing period, and is effective in the long term with no evidence of intolerance. The BP-lowering capacity of manidipine is similar to that of other established DHPs and of angiotensin-converting enzyme inhibitors. Diabetic patients and very elderly patients with mild-to-moderate hypertension also respond favourably to treatment with manidipine. Manidipine has neutral effects on glucose and lipid metabolism and is generally well tolerated. Manidipine thus represents a first-line option for lowering BP in patients with mild-to-moderate hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16398058     DOI: 10.2165/00003495-200565002-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  41 in total

1.  A study of the effects of manidipine on the diurnal variation of arterial pressure and hemodynamics in patients with essential hypertension.

Authors:  A Iwata; O Tochikubo; Y Kawano; K Minamisawa; Y Miyakawa; M Ishii
Journal:  Blood Press Suppl       Date:  1992

Review 2.  Pharmacokinetics of calcium antagonists.

Authors:  J L Reid; P A Meredith; R Donnelly; H L Elliott
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

3.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

4.  Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension.

Authors:  A Zanchetti; S Omboni; P La Commare; R De Cesaris; P Palatini
Journal:  J Cardiovasc Pharmacol       Date:  2001-10       Impact factor: 3.105

Review 5.  Treatment of hypertension in the elderly.

Authors:  A F Lever; L E Ramsay
Journal:  J Hypertens       Date:  1995-06       Impact factor: 4.844

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 7.  Worldwide prevalence of hypertension: a systematic review.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul K Whelton; Jiang He
Journal:  J Hypertens       Date:  2004-01       Impact factor: 4.844

8.  Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

Authors:  Jan A Staessen; Ji-Guang Wang; Lutgarde Thijs
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

9.  Effects of manidipine and delapril on serum lipids, lipoproteins, and apolipoproteins in patients with mild to moderate essential hypertension: a randomized trial with one-year follow-up.

Authors:  K Saku; B Zhang; K Hirata; R Liu; N Sasaki; T Sakai; H Ying; K Arakawa
Journal:  Clin Ther       Date:  1992 Nov-Dec       Impact factor: 3.393

Review 10.  Review: the central role of calcium in the pathogenesis of cardiovascular disease.

Authors:  H Haller; H L Elliott
Journal:  J Hum Hypertens       Date:  1996-03       Impact factor: 3.012

View more
  2 in total

1.  The effect of nimodipine on calcium homeostasis and pain sensitivity in diabetic rats.

Authors:  L Shutov; I Kruglikov; O Gryshchenko; E Khomula; V Viatchenko-Karpinski; P Belan; N Voitenko
Journal:  Cell Mol Neurobiol       Date:  2006-07-12       Impact factor: 5.046

2.  Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection.

Authors:  Shaobo Wang; Yang Liu; Jiao Guo; Peilin Wang; Leike Zhang; Gengfu Xiao; Wei Wang
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.